June 29 (Reuters) - Abivax said on Monday its experimental ulcerative colitis drug helped harder-to-treat groups of patients achieve remission, with the biotech calling the results a boost to the ...
Findings showed a significantly greater proportion of patients treated with the SC induction regimen achieved clinical remission, clinical response, and endoscopic improvement compared with placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results